GENinCode UK Ltd. (GB:GENI)
LSE:GENI
Want to see GB:GENI full AI Analyst Report?
GENI Stock Chart & Stats
2.20 p
0.20 p(5.56%)
At close: 4:00 PM EST
2.20 p
0.20 p(5.56%)
Day’s Range― - ―
52-Week Range0.85 p - 5.50 p
Previous CloseN/A
Volume6.76K
Average Volume (3M)1.99M
Market Cap
£6.78M
Enterprise Value952.88K
Total Cash (Recent Filing)£895.00K
Total Debt (Recent Filing)£146.00K
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
Bulls Say, Bears Say
Bulls Say
Specialized Genomics Diagnostic FocusGENinCode's focused business model on genomic tests for cardiovascular risk aligns the company with clinical decision workflows. This specialization creates durable technical and regulatory barriers, fosters deeper clinician and lab integration, and supports repeatable demand from healthcare providers as adoption grows over months to years.
Improving Gross Margin (~50% In 2025)A near-50% gross margin demonstrates improving unit economics in the core test business. Sustained margins at this level provide a structural foundation for future operating leverage: as revenue scales, gross-profit can absorb fixed R&D and SG&A, materially improving prospects for sustainable profitability over the medium term.
Revenue Growth AccelerationAn accelerating top-line indicates improving commercial traction for tests and services. Even modest percentage increases at current scale signal demand validation; sustained revenue growth enables leverage of the improving gross margin and helps justify continued investment in commercialization and product enhancements over the next 2-6 months and beyond.
Bears Say
Persistent Negative Free Cash FlowConsistent annual cash burn without a visible path to break-even increases reliance on external financing. This structural cash shortfall pressures management to raise capital or cut spend, which can dilute shareholders, slow commercialization, or constrain investment in regulatory and lab partnerships critical for long-term growth.
Deep And Widening Net LossesVery large negative margins indicate the cost base far exceeds current scale and that operating losses are structural today. Without clear expense scaling or revenue inflection, persistent unprofitability undermines sustainable cash generation and heightens the risk the business will require repeated funding rounds.
Weakened Equity And Higher LeverageMaterial equity erosion and a rising debt-to-equity ratio reduce financial flexibility and increase refinancing risk. With a thinner equity buffer, additional losses could trigger covenants or constrain borrowing, making the company more vulnerable to funding stress and limiting its ability to execute longer-term commercial strategies.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.85 p and its highest was 5.50 p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £6.78M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 111 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.01 p.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.01 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---